ArticleFrontiers in allergy2026
Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratio.
Article in Frontiers in allergy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The sIgE/sIgG4 ratio has been proposed as a dynamic measure of immune modulation during peanut oral immunotherapy (OIT). This study evaluated a chemiluminescent immunoassay for simultaneous quantification of peanut-specific sIgE and sIgG4 on the automated Autolumo A2000 Plus platform. Methods: Analytical performance was assessed for peanut, Ara h 2, and Ara h 6 sIgE and sIgG4. Method comparison with ImmunoCAP was performed across the measurable concentration range. In a separate retrospective pilot cohort of 23 peanut-allergic patients undergoing OIT, longitudinal sIgE, sIgG4 and sIgE/sIgG4 ratio trajectories were compared between A2000 and ImmunoCAP. Associations between ratio trajectories and OIT dose escalation were evaluated as an exploratory treatment-progression measure. Results: The A2000 Plus demonstrated high analytical sensitivity (sIgE LOQ < 0.05 kU/L; sIgG4 LOQ < 0.06 mg/L), precision (intra- and inter-assay CVs < 3% and <5%, respectively), and linearity (R² > 0.990). Method comparison with ImmunoCAP showed high positive percent agreement (82%-97%) and negative percent agreement (92%-100%), with strong concordance for log(sIgE) ( Conclusion: The Autolumo A2000 Plus demonstrated strong analytical performance and captured expected immunologic trends during peanut OIT. These findings support further investigation of this platform as a potential complementary monitoring tool in OIT. Larger prospective studies are required to establish clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.